Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials

Web Exclusives - Clinical Trials

San Diego, CA—New research sponsored by the National Cancer Institute highlights the uphill battle faced by patients with limited financial resources even in clinical trials. According to data presented at the 2019 ASCO Quality Care Symposium, patients with Medicaid or with no insurance had significantly worse overall survival in positive clinical trials compared with privately insured patients.

This meta-analysis of data collected from 19 clinical trials and more than 11,000 patients showed that underinsured patients had no observed benefit from experimental treatment in trials that had positive overall survival benefits. By contrast, positive treatment effects were observed for all other groups of patients.

“The magnitude of treatment benefits from experimental therapies may not be uniform for patients with Medicaid or no insurance,” said lead author of the study, Joseph M. Unger, PhD, SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA. “These patients are likely at a greater risk of experiencing competing risks of death, which can reduce power to identify the benefits of new experimental therapies.”

Understanding whether benefits are consistent among all patient groups is critical for informing clinical guidelines, but clinical trials are rarely powered to examine demographic or insurance subpopulations, especially in underrepresented groups.

“The generalizability of treatment effects to these subgroups is often simply assumed, and distinctions about treatment efficacy within subgroups are rarely made in cancer treatment guidelines,” said Dr Unger.

For this study, Dr Unger and colleagues examined whether positive treatment effects apply to all demographic and insurance groups. The researchers pooled data from all SWOG treatment trials completed between 1985 and 2014 with a statistically significant (P <.05) overall survival benefit in the experimental arm. They then looked at private versus Medicaid or no insurance status. Suboptimal insurance status was an indicator of low socioeconomic status at the patient level. Multivariable Cox regression models were used to identify whether survival patterns differed by demographic and insurance status factors.

Experimental Therapy Favors Privately Insured Patients

The final analysis included 19 trials with significantly better overall survival in the experimental arm, for a total sample size of more than 11,000 patients. Although overall survival treatment effects did not differ by sex, race, or ethnicity, patients with private insurance had a much greater benefit from the experimental therapy compared with patients with Medicaid or no insurance.

“One key takeaway is that underinsured patients had no observed benefit from the experimental therapy in trials where everybody else essentially had that benefit,” said Dr Unger, who noted that analysis of progression-free survival showed similar discrepancies.

Follow-up time from 0.1 year to 7.5 years was used to see when the interaction between insurance status and treatment became significant. The role of insurance status manifested itself very quickly within the first year of follow-up, he said.

“Thereafter, there’s nearly a constant influence of insurance status on treatment effects over time,” said Dr Unger. “Although this effect is more meaningful for overall survival than it is for progression-free survival, the effect is statistically significant for both end points within the first year.”

“Even in a setting in which patients are uniformly staged and treated under protocol care, suboptimal insurance influenced both cancer and noncancer outcomes,” Dr Unger concluded. “These findings may inform policy regarding continued resource support for patients beyond their initial treatment.”

Social Determinants Influence Outcomes

Nina A. Bickell, MD, MPH, Co-Director, Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, NY, said that these findings highlight the critical role of social determinants of health on clinical trial outcomes and the likely role of comorbidities.

“Although clinical trials frequently exclude individuals with certain comorbidities like congestive heart failure, other comorbid conditions that could affect overall survival may not be excluded,” said Dr Bickell, noting that access and adherence to treatments—not just for cancer, but for all of an individual’s medical challenges—can also affect survival.

In addition to making it easier for providers and patients in underserved communities to access clinical trials, researchers must also make sure that patients have insurance to help with comorbidity treatments, as well as with clinical trial costs, Dr Bickell said.

Related Items
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Web Exclusives published on October 4, 2021 in Biosimilars, ASCO Highlights
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Delivering High-Value Personalized Interventions
Chase Doyle
Web Exclusives published on December 9, 2019 in Clinical Trials
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.